Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Psoriatic arthritis (PsA) treatment typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics or targeted oral therapies as needed. The U.S. market for conventional DMARD-refractory patients is increasingly crowded with multiple efficacious therapies, including six TNF-alpha inhibitors, the IL-17 inhibitor Cosentyx (Novartis), the IL-12/23 inhibitor Stelara (Janssen), and the first-approved oral targeted PsA therapy, Otezla (Celgene). In addition, the December 2017 FDA approvals of Xeljanz (Pfizer), an additional oral, first-in-class JAK inhibitor, and Taltz (Eli Lilly), a second-in-class IL-17 inhibitor, have expanded physicians’ treatment armamentarium for PsA and further increased the competition.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Already a Client? Log in to access this report.
Ajay Puri is a Research Associate on the Immune and Inflammatory team at Decision Resources Group. He currently focuses on Inflammatory bowel disease (IBD). He holds a bachelor’s degree in Pharmacy and has earned his MBA in Pharmaceutical marketing from NIPER, Mohali. Prior to joining DRG, Ajay worked as a Business Research Associate (Oncology) at ZS Associates. He has worked on multiple client projects revolving around competitive intelligence, opportunity assessment, trend analysis, clinical trial analysis, and product/company profiling.